Market News

Ocular Therapeutics’ (NASDAQ:OCUL) Wet AMD Interim Phase 1 Data Shows Promise

Ocular Therapeutics (NASDAQ:OCUL) has reported positive interim 7-month data for the Phase 1 trial of its implant (OTX-TKI) being developed for wet age-related macular degeneration (Wet AMD) as well as other retinal ailments.

OTX-TKI demonstrated a favorable safety profile, was well tolerated and a detailed presentation of the data is expected on Friday at the American Academy of Ophthalmology (AAO) 2022 annual meeting.

Wet AMD affects about 14 million people worldwide and is a leading cause of blindness.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed